valdecoxib


Also found in: Dictionary, Thesaurus, Wikipedia.
Related to valdecoxib: rofecoxib, Parecoxib

valdecoxib

/val·de·cox·ib/ (val″dĕ-kok´sib) a nonsteroidal antiinflammatory drug of the COX-2 inhibitors group, used for the treatment of osteoarthritis, rheumatoid arthritis, and primary dysmenorrhea.

valdecoxib

a nonsteroidal antiinflammatory used to treat acute and chronic rheumatoid arthritis, osteoarthritis, and primary dysmenorrhea.

Bextra

A next-generation NSAID Cox-2 inhibitor used for managing pain due to osteoarthritis, rheumatoid arthritis, dysmenorrhea, etc.
 
Adverse effects
Rarely, serious skin and hypersensitivity reactions (e.g., Stevens Johnson syndrome); toxic epidermal necrolysis; exfoliative dermatitis; erythema multiforme, possibly requiring hospitalisation; Bextra is contraindicated with sulfa drugs.

valdecoxib

See Bextra®.

valdecoxib

A COX-2 inhibitor drug used to treat OSTEOARTHRITIS, RHEUMATOID ARTHRITIS and DYSMENORRHOEA. A brand name is Bextra. In late 2004 the drug was shown to have cardiotoxic properties similar to those of rofecoxib and it was recommended that the drug should be withdrawn.
Mentioned in ?
References in periodicals archive ?
Valdecoxib, a cyclooxygenase-2-specific inhibitor, is effective in treating primary dysmenorrhea.
A randomised comparison of parecoxib versus placebo for pain management following minor day stay gynaecological surgery
To this 1 ml of Valdecoxib (2 [micro]g/ml) was added and then the mixture was sonicated for 20 min and then filtered.
Simultaneous estimation of paracetamol and tramadol in tablet formulation by reverse phase HPLC method
Some of the most selective drugs, like celecoxib and valdecoxib, are on the lower side," Dr.
Study supports NSAID class effect on MI risk: coxibs no more a factor than non-COX-2
In early April 2005, the FDA asked the manufacturer (Pfizer) to withdraw valdecoxib (Bextra) from the market because the overall risk versus benefit profile for the drug was found to be unfavorable.
Pain Management; Treatment
I would like more investigations into Valdecoxib to take place.
Appeal for drug probe
There is no available alternative for migraine sufferers yet, though Pfizer's valdecoxib is currently awaiting approval for this indication.
Pfizer Likely to Benefit From Vioxx Withdrawal, Notes Pharmaprojects
Valdecoxib for postoperative pain management after cesarean delivery: a randomized, double-blind, placebo-controlled study.
Analgesia after caesarean delivery
Both valdecoxib in its clinical exposure and celecoxib in ankylosing spondylitis show similar results.
The COX 2 selective inhibitors: what the newspapers have not told you
There was no increased risk for those using celecoxib or valdecoxib.
After rofecoxib, CV risks warrant close monitoring
One thing is for certain: A simple, safe, analgesic patch would be welcome news for patients and physicians beleaguered by the withdrawals of rofecoxib (Vioxx) and valdecoxib (Bextra) and the addition of a black box warning on celecoxib.
Could a lidocaine patch plug the COX-2 gap?
What's more, later in 2004, FDA issued a warning about heart risks linked to a related drug, valdecoxib (Bextra), and manufacturer Pfizer stopped consumer advertising of a third such drug, celecoxib (Celebrex), because of worrisome new cardiovascular findrags.
Dangerous practices: critics see flaws in drug-safety monitoring
parecoxib, the injectable prodrug of valdecoxib, for treatment of acute
Final Results

Medical browser ?
Full browser ?